Emeramide ( DrugBank: Emeramide )


2 diseases
IDDisease name (Link within this page)Number of trials
5Progressive supranuclear palsy1
17Multiple system atrophy1

5. Progressive supranuclear palsy


Clinical trials : 89 Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000506-34-SI
(EUCTR)
04/02/201909/03/2018EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 PSP or MSA;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: NBMI
Product Code: NBMI
INN or Proposed INN: emeramide
Other descriptive name: N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE
NBMI Science Ltd.NULLNot RecruitingFemale: yes
Male: yes
20Phase 2Slovenia

17. Multiple system atrophy


Clinical trials : 119 Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000506-34-SI
(EUCTR)
04/02/201909/03/2018EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 PSP or MSA;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: NBMI
Product Code: NBMI
INN or Proposed INN: emeramide
Other descriptive name: N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE
NBMI Science Ltd.NULLNot RecruitingFemale: yes
Male: yes
20Phase 2Slovenia